OncoSec Medical Appoints Engineering Leader

SAN DIEGO, July 5, 2011 /PRNewswire/ — OncoSec Medical Inc.
(OTCBB: ONCS), which is developing its advanced-stage
ElectroOncology therapies to treat solid tumor cancers, announced
today the appointment of Brian McCluskey as Executive Director,
Engineering, who will lead the development of the company’s
proprietary electroporation delivery technology, the OncoSec
Medical System (OMS).

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Punit Dhillon, OncoSec’s President and CEO, said, “We are
pleased that Brian will join  our management team. He brings a
proven track record of medical device design and technical
leadership experience, with the ability to design, manage and
coordinate the development of medical devices from concept to
production. Brian will be instrumental in developing OncoSec’s next
generation OMS products.”

OncoSec’s minimally invasive ElectroOncology therapies utilize
its proprietary electroporation delivery system, called the OncoSec
Medical System (OMS), which applies short electrical impulses to
selectively targeted tumors and tissue in order to significantly
increase the ability of anti-cancer chemotherapeutic or biologic
agents to enter into cells. These treatments selectively destroy
cancer cells while preserving healthy tissue. They optimize
required dosage and potentially reduce treatment and post-treatment
costs.

Brian McCluskey, Executive Director, Engineering

Mr. McCluskey has more than 30 years of electrical engineering
experience, in which he has spent the last 20 years developing
software and hardware for devices used for medical and research
purposes. Through this, he has managed successful submissions for
FDA 510(k) approvals, as well as, CE marks for marketing in Europe.
Mr. McCluskey was recently with Teledyne RD Instruments (TRDI), a
leader in the design and manufacture of Doppler instrumentation,
f

‘/>”/>

SOURCE